{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/asthma/prescribing-information/beta-2-agonists/","result":{"pageContext":{"chapter":{"id":"5eb1288c-29af-59c1-b623-bd0010732835","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists","depth":2,"htmlHeader":"<!-- begin field cbd78448-fb44-4e1b-ae6b-a6d7016a65e8 --><h2>Beta-2 agonists</h2><!-- end field cbd78448-fb44-4e1b-ae6b-a6d7016a65e8 -->","summary":"","htmlStringContent":"<!-- begin item be2c12ab-d9dd-4ccf-bbda-a6d7016a5f43 --><!-- begin field d18b91d7-0383-466f-b13e-a6d7016a65e8 --><ul><li><strong>Beta-2 agonists — act directly on beta-2 receptors, causing smooth muscle relaxation and dilatation of the airways.</strong></li><li><strong>Short-acting beta-2 agonists (SABAs),</strong> such as salbutamol and terbutaline, have a rapid onset of action (15 minutes) and their effects last for up to 4 hours.<ul><li>Doses vary depending on the person's age, response to treatment and the preparation prescribed. For more details, see the <a href=\"https://www.evidence.nhs.uk/formulary/bnf/current\" data-hyperlink-id=\"02946b15-5a02-4ace-bedc-a8f7014ed320\">British National Formulary</a> and the manufacturers' Summaries of Product Characteristics.</li><li>Use of a SABA as required is at least as effective as regular (four times daily) use. </li></ul></li><li><strong>Long-acting beta-2 agonists (LABAs)</strong> have prolonged receptor occupancy. Salmeterol and formoterol are relatively lipophilic and have a duration of action of 12 hours.<ul><li>They should only be used in people who regularly use an inhaled corticosteroid.</li><li>A LABA should be introduced at a low dose and the effect monitored before considering a dose increase.</li><li>The recommended doses vary depending on the person's age, response to treatment and the preparation prescribed. For more details, see the <a href=\"https://www.evidence.nhs.uk/formulary/bnf/current\" data-hyperlink-id=\"2399ef73-433e-4b8c-aa53-a8f7014ed329\">British National Formulary</a> and the manufacturers' Summaries of Product Characteristics.</li><li>Combination products that include a LABA and an inhaled corticosteroid are available, such as formoterol plus budesonide, formoterol plus beclometasone, and salmeterol plus fluticasone propionate. Some preparations of formoterol plus budesonide are licensed for use in people over the age of 12 years, and formoterol plus beclometasone are licensed for use in people over the age of 18 years, as maintenance and reliever therapy. The appropriate inhaler should be prescribed by brand name. For more details, see the <a href=\"https://www.evidence.nhs.uk/formulary/bnf/current\" data-hyperlink-id=\"c9f36305-50ff-49d6-8864-a8f7014ed329\">British National Formulary</a>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">BNF 75, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">BTS/SIGN, 2019</a>]</p><!-- end field d18b91d7-0383-466f-b13e-a6d7016a65e8 --><!-- end item be2c12ab-d9dd-4ccf-bbda-a6d7016a5f43 -->","topic":{"id":"d631356f-d3a3-51fb-807c-5517c470a5af","topicId":"2a0a90e6-1c4e-4b6a-9ce2-3379dd122594","topicName":"Asthma","slug":"asthma","lastRevised":"Last revised in October 2020","chapters":[{"id":"c7185669-75fd-5c6e-b105-63a3237634ac","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9fe1ab10-4b4d-5ba8-9ef0-00631cd00ea4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"770d55df-2c61-5d1e-83d9-92b12ccae96a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d2031db2-44fd-55bb-b5c8-d085b387747a","slug":"changes","fullItemName":"Changes"},{"id":"a993bde1-1ac8-529e-8a3e-201a8c082ab2","slug":"update","fullItemName":"Update"}]},{"id":"eae8fe92-3941-512e-bcc6-f1e15157c1ae","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8e125759-cd9d-510d-9659-3c2e77baa755","slug":"goals","fullItemName":"Goals"},{"id":"a6c91cd5-1ce2-5c60-86cc-341a9dccf3d4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a5746054-2f36-5a42-9e7c-7af9107ad99b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5fd19cd9-6ac7-54c8-89be-817d58e41309","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f7339086-c653-53dd-990c-6d470fa223b8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f43b79db-3c62-58ee-bb70-932e6613eea6","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0d12a387-5436-5c75-92c0-189cb391ec7a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8fbe04ed-5fd7-54c9-be84-6c959f75af3b","slug":"definition","fullItemName":"Definition"},{"id":"5cbe6206-f80c-5a71-8e4d-a4d44e392874","slug":"prevalence","fullItemName":"Prevalence"},{"id":"2fb588ab-6181-5aec-8a4a-fb368098329d","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"b786654f-5e6e-5e5f-9ead-abaca7f99ba5","slug":"prognosis","fullItemName":"Prognosis"},{"id":"c0b65c0b-957e-538e-83e9-5b4af2d8e6dd","slug":"complications","fullItemName":"Complications"}]},{"id":"574c6193-f36f-5bf7-946a-d8c688476131","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"351773e5-286c-5560-8402-79c2d92d4aa6","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"053272da-fea9-5df6-842a-0de682896aaf","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"7b632c20-012f-590e-a01e-cda5715d6f14","fullItemName":"Management","slug":"management","subChapters":[{"id":"f95fb73f-b749-53a5-b857-4d2bb9945667","slug":"newly-diagnosed-asthma","fullItemName":"Scenario: Newly-diagnosed asthma"},{"id":"2878c5f8-3e3f-52c8-a9bd-7988906b6f99","slug":"follow-up","fullItemName":"Scenario: Follow-up"},{"id":"2458c073-8efb-5a81-8bc4-9a543deab17d","slug":"acute-exacerbation-of-asthma","fullItemName":"Scenario: Acute exacerbation of asthma"},{"id":"45a1b06c-1e5d-56b4-8da7-a8abf4f6c7cc","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"fb9dc424-4306-54a1-b06b-1b01273ac473","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"52940123-8084-55c3-b593-cc9fe50daf8f","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"5eb1288c-29af-59c1-b623-bd0010732835","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"},{"id":"dc8f7545-ff7a-5bf1-8ac8-95161137fac5","slug":"inhaled-corticosteroids","fullItemName":"Inhaled corticosteroids"},{"id":"4d715496-c821-52e3-8ea0-d05cfb33d3eb","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"d8174f33-d787-5076-88b5-f4c67df93128","slug":"leukotriene-receptor-antagonists","fullItemName":"Leukotriene receptor antagonists"},{"id":"a556cd4f-1851-52fd-a993-34e977a27fd2","slug":"muscarinic-agents","fullItemName":"Muscarinic agents"},{"id":"0cea3b69-b77b-505e-bded-6fceaca145df","slug":"theophylline","fullItemName":"Theophylline"},{"id":"550429f1-7cab-5f16-b476-e479d8084c03","slug":"cromones","fullItemName":"Cromones"}]},{"id":"76b3dfce-ba54-5456-a259-79b345a5e064","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e31b3681-17cc-5ff2-ba28-d3b1fcb0a82c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2bcf3eeb-fd2e-5d40-a52f-da626afbbe01","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"14ea4312-4846-5381-a82c-dc6b03a60d04","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e4987bc8-0a78-59eb-bfda-f9de7c9ee182","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"be4f3045-8192-53b7-81a3-b460bb2218bc","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"82ae443c-942c-5053-a988-38bce8dec570","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"efdf3cf8-dee5-5351-9d2d-346b4fdf9faf","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"fb9dc424-4306-54a1-b06b-1b01273ac473","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"06b15041-3d44-553d-a512-443aa42f069c","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 8dc3d133-50f9-43fb-9d07-a6d80145dc41 --><h3>Contraindications and cautions</h3><!-- end field 8dc3d133-50f9-43fb-9d07-a6d80145dc41 -->","summary":"","htmlStringContent":"<!-- begin item 07fffe25-13a0-42f9-a8ba-a6d80145d84d --><!-- begin field 180a99d0-e5b4-4be4-bc6e-a6d80145dc41 --><ul><li><strong>Beta-2 agonists should be used with caution in people with:</strong><ul><li>Hyperthyroidism — beta-2 agonists may stimulate thyroid activity.</li><li>Diabetes mellitus — there is a rare risk of ketoacidosis (especially after intravenous beta-2 agonist administration). Additional blood glucose measurements are recommended when treatment with a beta-2 agonist is commenced.</li><li>Cardiovascular disease (including hypertension) — beta-2 agonists may cause an increased risk of arrhythmias and significant changes to blood pressure and heart rate.</li><li>Susceptibility to QT-interval prolongation.</li><li>Hypokalaemia — plasma potassium concentration may be reduced by beta-2 agonists (particularly high doses).</li><li>Convulsive disorders.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">BNF 75, 2018</a>]</p><!-- end field 180a99d0-e5b4-4be4-bc6e-a6d80145dc41 --><!-- end item 07fffe25-13a0-42f9-a8ba-a6d80145d84d -->","subChapters":[]},{"id":"0134e6eb-3417-52a9-9ff3-0f768effb50f","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field b4c3fcba-15cb-4e25-a9e5-a6d80145f98c --><h3>Adverse effects</h3><!-- end field b4c3fcba-15cb-4e25-a9e5-a6d80145f98c -->","summary":"","htmlStringContent":"<!-- begin item 2c669cbf-22b0-4a0b-b734-a6d80145f3f9 --><!-- begin field cb56f451-8c91-4e37-9cba-a6d80145f98c --><ul><li><strong>Adverse effects of short-acting and long-acting beta-2 agonists are similar. They are usually dose related and include:</strong><ul><li>Fine tremor — occurs particularly in the hands and is usually worse in the first few days of treatment.</li><li>Palpitations.</li><li>Headache.</li><li>Seizure.</li><li>Anxiety.</li><li>Hypokalaemia.</li><li>Cardiac arrhythmia and paradoxical bronchospasm (rare).</li><li>Acute angle-closure glaucoma has been reported in people using nebulized short-acting beta-2 agonists.<ul><li>Advise people using nebulized short-acting beta-2 agonists to use a mouthpiece rather than a mask to minimize exposure of the eyes to the drug.</li></ul></li></ul></li><li>Advise people who are using terbutaline turbohaler to rinse their mouth with water after each use. A fraction of the dose will always be deposited in the mouth and rinsing will minimize the amount of drug that is absorbed systemically.</li><li><strong>The risk of adverse events may be higher in people with a predisposition to arrhythmias and in people with pre-existing cardiovascular disease, or hypertension.</strong></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">ABPI Medicines Compendium, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">BNF 75, 2018</a>]</p><!-- end field cb56f451-8c91-4e37-9cba-a6d80145f98c --><!-- end item 2c669cbf-22b0-4a0b-b734-a6d80145f3f9 -->","subChapters":[]},{"id":"40c93ac7-58c4-5be9-88d4-7a4e34025518","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 4f0957d3-c135-4a3f-b034-a6d80146193f --><h3>Drug interactions</h3><!-- end field 4f0957d3-c135-4a3f-b034-a6d80146193f -->","summary":"","htmlStringContent":"<!-- begin item a4504b51-f61f-44a4-b090-a6d80146157d --><!-- begin field 3d94e210-56c8-423f-81dd-a6d80146193f --><ul><li><strong>Corticosteroids, diuretics, and xanthine derivatives such as theophylline</strong> — monitor potassium levels.<ul><li>Beta-2 agonists can cause hypokalaemia (particularly at high doses), and this can be increased by other potassium-depleting drugs, such as corticosteroids, loop diuretics, and xanthine derivatives.</li></ul></li><li><strong>Digoxin </strong>— monitor potassium levels and be alert to signs of digoxin toxicity, such as loss of appetite, nausea, vomiting, bradycardia, visual disturbance, and drowsiness.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">BNF 75, 2018</a>]</p><!-- end field 3d94e210-56c8-423f-81dd-a6d80146193f --><!-- end item a4504b51-f61f-44a4-b090-a6d80146157d -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}